Carnegie acted as joint bookrunner in the directed new share issue of 4,750,000 shares at a subscription price of SEK 115 per share. Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. January 2019.
Healthcare
Directed new share issue in Oncopeptides AB (SE) — SEK 546 million
January 2019